Latest Asx Listing News

OZZ Resources moves closer to acquiring Sulphide Minerals and regaining ASX listing with a $5 million capital raise, while navigating legal challenges on key tenements.

Careteq Limited (ASX: CTQ) has confirmed it will maintain its ASX listing after selling its Embedded Health Solutions subsidiary, shifting its strategic focus entirely to its HMR Referrals platform. The company reported positive operating cash flow in the March quarter and outlined plans to expand its pharmacist and GP networks while exploring AI and adjacent healthcare opportunities.

Patronus Resources has kicked off its 2026 exploration season with promising high-grade gold results at the Tally Ho deposit in the Northern Territory and secured full ownership of the Guppy prospect in Western Australia, while executing a strategic uranium rights sale.

Tissue Repair Limited (ASX: TRP) has applied to delist from the ASX, citing limited liquidity and high listing costs. The company plans a shareholder vote and a $1 million off-market buy-back at a premium to recent prices.

Monvia Limited, an Australian SaaS provider for life insurers, is seeking to raise $17.5 million via an IPO on the ASX. The funds will support redemption of preference shares and fuel growth in existing and new markets.

Papyrus Australia has tapped related party L39 Capital to lead a capital raise and secured an interest-bearing $200,000 loan from Irwin Biotech, with conversion into shares and options pending shareholder approval.

Amaero Inc. capped FY2026 with a record A$18.1 million revenue, expanded its production capacity, and landed a A$6.5 million US Department of War contract to develop alternative refractory alloy powders.

Alurion Resources has closed its IPO at the maximum subscription of A$50 million, setting the stage for an expanded development program at its Amargosa Bauxite-Gallium Project. Brazilian Rare Earths retains a strategic 16% stake as Alurion prepares for ASX listing.

Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Flagship Minerals has received full payment of US$4 million for its RK Lithium Project sale, advancing its strategic pivot towards gold and copper assets in Chile and Canada.

Koonenberry Gold Limited has locked in $4 million through a share placement to accelerate drilling and geochemical studies across its NSW projects, including the newly acquired Gundagai.